Multiple Myeloma Coverage from Every Angle

Francesca Gay, MD, on the FORTE Trial: Triplet Therapy for Newly Diagnosed Multiple Myeloma

Posted: Monday, June 10, 2019

Francesca Gay, MD, of GIMEMA, European Myeloma Network, discusses the potential role of carfilzomib/lenalidomide/dexamethasone with or without transplantation in inducing high-quality responses, achieving negative minimal residual disease, and reducing the risk of early relapse.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.